EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacological HIF-PH Inhibition Suppresses Myoblast Differentiation Through Continued HIF-1α Stabilization

Yuya Miki, Akinobu Ochi iD, Hideki Uedono, Yoshinori Kakutani, Mitsuru Ichii, Yuki Nagata iD, Katsuhito Mori iD, Yasuo Imanishi, Tetsuo Shoji iD, Tomoaki Morioka iD, Masanori Emoto

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26115410 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yuya Miki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan. Hauptthemen laut MEDLINE: Hypoxia-Inducible Factor 1, alpha Subunit, Cell Differentiation, Myoblasts, Hypoxia-Inducible Factor-Proline Dioxygenases. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Osaka Medical Research Foundation for Intractable Diseases, Osaka Medical Research Foundation for Intractable Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors continually stabilize hypoxia-inducible factor-1α (HIF-1α). These inhibitors are effective in the clinical treatment of renal anemia. However, the effects of continued HIF-1α stabilization on skeletal muscle differentiation remain unclear. This study aimed to investigate the effects of continued HIF-1α stabilization on skeletal muscle differentiation using a HIF-PH inhibitor in both in vitro and in vivo models. We cultured mouse C2C12 myoblasts to differentiate into myotubes with or without FG-4592, a HIF-PH inhibitor. Additionally, we treated nine-week-old male C57BL/6 mice with either FG-4592 or vehicle via intraperitoneal injections three times a week for four weeks. In vitro, FG-4592 treatment stabilized HIF-1α continually. Morphological analysis revealed that 72 h FG-4592 treatment suppressed differentiation of C2C12 myoblasts into myotubes. This treatment decreased the gene and protein expression of MyoD and myogenin, reduced the protein expression of myosin heavy chain (MHC), and increased the gene and protein expression of myostatin. HIF-1α knockdown mitigated the decrease in MHC protein expression induced by FG-4592. In vivo, FG-4592 treatment increased HIF-1α protein expression and decreased MyoD, myogenin, and MHC protein expression in gastrocnemius muscle. These findings suggest that pharmacological HIF-PH inhibition suppresses myoblast differentiation through continued HIF-1α stabilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypoxia-Inducible Factor 1, alpha SubunitCell DifferentiationMyoblastsHypoxia-Inducible Factor-Proline DioxygenasesProlyl-Hydroxylase InhibitorsAnimalsMiceMaleMice, Inbred C57BLCell LineMuscle Fibers, SkeletalMyogeninProtein StabilityMuscle DevelopmentMuscle, SkeletalMyoD Protein

Stichwörter der Autor:innen

HIF-1α stabilizationHIF-PH inhibitormuscle differentiation

Substanzen

Hypoxia-Inducible Factor 1, alpha SubunitHif1a protein, mouseHypoxia-Inducible Factor-Proline DioxygenasesMyogeninMyoD ProteinProlyl-Hydroxylase Inhibitors

Autor:innen und Institutionen

  • Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
  • Division of Internal Medicine, Inoue Hospital, Osaka 564-0053, Japan.
  • Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
  • Vascular Science Center for Translational Research, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.
  • Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine, Osaka 545-8585, Japan.

ORCID-Profile: Akinobu Ochi, Yuki Nagata, Katsuhito Mori, Tetsuo Shoji, Tomoaki Morioka

Förderung

  • The Osaka Medical Research Foundation for Intractable Diseases
  • Osaka Medical Research Foundation for Intractable Diseases

Zitieren

APA

Miki, Y., Ochi, A., Uedono, H., Kakutani, Y., Ichii, M., Nagata, Y., Mori, K., Imanishi, Y., Shoji, T., Morioka, T., & Emoto, M. (2025). Pharmacological HIF-PH Inhibition Suppresses Myoblast Differentiation Through Continued HIF-1α Stabilization. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115410

Vancouver

Miki Y, Ochi A, Uedono H, Kakutani Y, Ichii M, Nagata Y, et al. Pharmacological HIF-PH Inhibition Suppresses Myoblast Differentiation Through Continued HIF-1α Stabilization. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115410

BibTeX
@article{Miki2025,
  author = {Miki, Yuya and Ochi, Akinobu and Uedono, Hideki and Kakutani, Yoshinori and Ichii, Mitsuru and Nagata, Yuki and Mori, Katsuhito and Imanishi, Yasuo and Shoji, Tetsuo and Morioka, Tomoaki and Emoto, Masanori},
  title = {Pharmacological HIF-PH Inhibition Suppresses Myoblast Differentiation Through Continued HIF-1α Stabilization},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26115410}
}
Kostenlos starten →